The last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSD
Topline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected by the end of September 2023
An end-of-phase 2 (EoPh2) meeting with the U.S. Food and Drug Administration (FDA) has been scheduled for September 2023 to review results from the Phase 2 PREVAIL study in patients with Social Anxiety Disorder (SAD) and to obtain feedback on a proposed Phase 3 registrational program
Bionomics is scheduled to delist from the Australian Securities Exchange on 28 August 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.